Molecular Medicine

, Volume 21, Issue 1, pp 364–370 | Cite as

Interleukin-9 Is Associated with Elevated Anti-Double-Stranded DNA Antibodies in Lupus-Prone Mice

  • Ji Yang
  • Qiao Li
  • Xue Yang
  • Ming Li
Research Article


Interleukin (IL)-9, which is produced mainly by CD4+ T cells, is implicated in mast cell-related allergic diseases, although its involvement in systemic lupus erythematosus (SLE) pathogenesis remains unclear. Thus, we investigated the presence of IL-9 in lupus-prone MRL/Mp-lpr/lpr (MRL/lpr) mice and examined the role of IL-9 in lupus pathogenesis. Increased levels of IL-9+ lymphocytes were detected in the spleens and kidneys of MRL/lpr mice and increased IL-9 levels in the spleen correlated with PNA+ germinal center (GC) cell expansion. The percentage of CD4+IL-9+ (Th9) cells was increased in MRL/lpr mice and serum IL-9 levels were elevated and closely related to the production of antibodies against double-stranded DNA (dsDNA). IL-9 appears to promote B-cell proliferation and immunoglobulin production, which could be blocked by inhibition of signal transducer and activator of transcription 3 (STAT3). Treatment with neutralizing anti-IL-9 antibody in vivo decreased serum anti-dsDNA-antibody titers and alleviated lupus nephritis in MRL/lpr mice. Our findings indicate expansion of Th9 cells in lupus-prone MRL/lpr mice and the correlation of IL-9 with B-cell proliferation and autoantibody production. These findings suggest that IL-9 is a potential therapeutic target for SLE.



We thank Haiying Zeng for histology and immunohistochemistry slide preparation. This work was supported by grants from the National Natural Science Foundation of China (nos. 81472874; 8100069; 81401346), Medical Guide Project from Shanghai Municipal Science and Technology (134119a8400), Shanghai Municipal Science and Technology (15ZR1406500) and the Shanghai Young Doctor Cultivation Plan.

Supplementary material

10020_2015_2101364_MOESM1_ESM.pdf (738 kb)
Supplementary material, approximately 738 KB.


  1. 1.
    Arbuckle MR, et al. (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349:1526–33.CrossRefGoogle Scholar
  2. 2.
    Veldhoen M, et al. (2008) Transforming growth factor-beta ‘reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat. Immunol. 9:1341–6.CrossRefGoogle Scholar
  3. 3.
    Dardalhon V, et al. (2008) IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat. Immunol. 9:1347–55.CrossRefGoogle Scholar
  4. 4.
    Putheti P, et al. (2010) Human CD4 memory T cells can become CD4+IL-9+ T cells. PLoS One. 5:e8706.CrossRefGoogle Scholar
  5. 5.
    Yao W, et al. (2013) Interleukin-9 is required for allergic airway inflammation mediated by the cytokine TSLP. Immunity. 38:360–72.CrossRefGoogle Scholar
  6. 6.
    Schmitt E, Klein M, Bopp T. (2014) Th9 cells, new players in adaptive immunity. Trends Immunol. 35:61–8.CrossRefGoogle Scholar
  7. 7.
    Kaplan MH. (2013) Th9 cells: differentiation and disease. Immunol. Rev. 252:104–15.CrossRefGoogle Scholar
  8. 8.
    Ouyang H, et al. (2013) Increased interleukin-9 and CD4+IL-9+ T cells in patients with systemic lupus erythematosus. Mol. Med. Rep. 7:1031–7.CrossRefGoogle Scholar
  9. 9.
    Yang J, et al. (2009) Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 60:1472–83.CrossRefGoogle Scholar
  10. 10.
    Yang J, et al. (2011) Recovery of the immune balance between Th17 and regulatory T cells as a treatment for systemic lupus erythematosus. Rheumatology. 50:1366–72.CrossRefGoogle Scholar
  11. 11.
    Crispin JC, Tsokos GC. (2010) Interleukin-17-producing T cells in lupus. Curr. Opin. Rheumatol. 22:499–503.CrossRefGoogle Scholar
  12. 12.
    Doreau A, et al. (2009) Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat. Immunol. 10:778–85.CrossRefGoogle Scholar
  13. 13.
    Elyaman W, et al. (2009) IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 106:12885–90.CrossRefGoogle Scholar
  14. 14.
    Soroosh P, Doherty TA. (2009) Th9 and allergic disease. Immunology. 127:450–8.CrossRefGoogle Scholar
  15. 15.
    Kim MS, et al. (2013) Effects of interleukin-9 blockade on chronic airway inflammation in murine asthma models. Allergy Asthma Immunol. Res. 5:197–206.CrossRefGoogle Scholar
  16. 16.
    Kezic JM, et al. (2012) Neutralization of IL-17 ameliorates uveitis but damages photoreceptors in a murine model of spondyloarthritis. Arthritis Res. Ther. 14:R18.CrossRefGoogle Scholar
  17. 17.
    Watson ML, et al. (1992) Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J. Exp. Med. 176:1645–56.CrossRefGoogle Scholar
  18. 18.
    Nowak EC, Noelle RJ. (2010) Interleukin-9 as a T helper type 17 cytokine. Immunology. 131:169–73.CrossRefGoogle Scholar
  19. 19.
    Lu Y, et al. (2014) Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers. Proc. Natl. Acad. Sci. U. S. A. 111:2265–70.CrossRefGoogle Scholar
  20. 20.
    Kim HS, Chung DH. (2013) IL-9-producing invariant NKT cells protect against DSS-induced colitis in an IL-4-dependent manner. Mucosal Immunol. 6:347–57.CrossRefGoogle Scholar
  21. 21.
    Fawaz LM, et al. (2007) Expression of IL-9 receptor alpha chain on human germinal center B cells modulates IgE secretion. J. Allergy Clin. Immunol. 120:1208–15.CrossRefGoogle Scholar
  22. 22.
    Avery DT, et al. (2010) B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J. Exp. Med. 207:155–71.CrossRefGoogle Scholar
  23. 23.
    Liu J, et al. (2014) IL-9 regulates allergen-specific Th1 responses in allergic contact dermatitis. J. Invest. Dermatol. 134:1903–11.CrossRefGoogle Scholar
  24. 24.
    Ma L, et al. (2014) Possible pathogenic role of T helper type 9 cells and interleukin (IL)-9 in atopic dermatitis. Clin. Exp. Immunol. 175:25–31.CrossRefGoogle Scholar
  25. 25.
    Yanaba K, et al. (2011) Serum interleukin 9 levels are increased in patients with systemic sclerosis: association with lower frequency and severity of pulmonary fibrosis. J. Rheumatol. 38:2193–7.CrossRefGoogle Scholar
  26. 26.
    Leng RX, et al. (2012) Potential roles of IL-9 in the pathogenesis of systemic lupus erythematosus. Am. J. Clin. Exp. Immunol. 1:28–32.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Wang L, et al. (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 206:1457–64.CrossRefGoogle Scholar
  28. 28.
    Goswami R, Kaplan MH. (2011) A brief history of IL-9. J. Immunol. 186:3283–8.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2015

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (

Authors and Affiliations

  1. 1.Department of Dermatology, Zhongshan HospitalFudan UniversityShanghaiChina
  2. 2.Department of Dermatology, Huashan HospitalFudan UniversityShanghaiChina
  3. 3.Division of Rheumatology, Huashan HospitalFudan UniversityShanghaiChina
  4. 4.Institute of Rheumatology, Immunology and AllergyFudan UniversityShanghaiChina

Personalised recommendations